Quest for Growth has announced that Wilex AG, its portfolio company, has successfully placed new shares in its IPO on the Frankfurt exchange. Wilex is a biopharmaceutical company based in Munich, which was founded in 1997 by a team of physicians and oncologists from the technical university of Munich. The company focuses on the development of new cancer therapies based on antibodies and small molecules which target the prevention of growth, spread and metastasis of malignant tumours and the destruction of malignant tumours in the body.
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater